Auro Laboratories Limited has submitted Financial Results for the quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Auro Laboratories, a small-cap pharmaceutical company, submitted its Q3 FY26 standalone results to BSE. Revenue from operations for the nine months ended December 2025 stood at around Rs 20.09 crore versus Rs 11.86 crore in the same period last year, indicating roughly 70% year-on-year growth. Profit after tax for the nine-month period more than doubled to about Rs 2.6 crore from Rs 1.16 crore previously. Q3 FY26 standalone PAT was around Rs 1.55 crore versus Rs 71.58 lakh in the prior corresponding quarter. Basic EPS for Q3 FY26 was approximately Rs 4.3, against Rs 7.5 for the full FY25. The statutory auditor B.L. Dasharda & Associates issued an unqualified limited review report with no qualifications, going-concern issues, or emphasis-of-matter items. The company continues to operate as a single segment (Pharmaceuticals) and has made a small Rs 3.08 lakh provision relating to the newly notified Labour Codes.
Strong top-line and bottom-line growth on a year-on-year basis is a positive signal for shareholders, though investors should keep in mind this is a small company where single-quarter figures can be volatile. The clean audit and absence of any red flags in the report support a stable near-term outlook.